Of these MAL-associated serum glycoproteins, Gal-3BP was further validated as a promising candidate for diagnosing early HCC; this result further confirmed that the combined use of serum Gal-3BP and serum AFP might serve as a potential marker for distinguishing early HCC patients with chronic HBV infection from healthy controls in the Chinese population. This evidence concerns the gene AFP and hepatocellular carcinoma.